Authors
Loading...
Expert review reveals advancing somatostatin receptor-targeted therapies in neuroendocrine neoplasms, highlighting novel radioligands and oral agents to overcome resistance.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: